Spruce Biosciences is a late-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Their flagship product candidate, tildacerfont, is a CRF 1 receptor antagonist currently in late-stage trials for adult patients with classic congenital adrenal hyperplasia (CAH), and a Phase 2 trial for pediatric classic CAH. Spruce aims to revolutionize the treatment of classic CAH by offering a well-tolerated, non-steroidal approach that improves disease control and reduces steroid burden for patients.

In addition to classic CAH, tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), such as a rare form of polycystic ovary syndrome (PCOS). Spruce is committed to advancing the treatment paradigm for rare endocrine disorders and providing effective therapies to patients with limited treatment options. Led by a team of experienced leaders in the biotechnology and pharmaceutical industries, including CEO Javier Szwarcberg and President Samir Gharib, Spruce embraces strategic collaborations with companies that share their mission.

They are actively seeking partnership opportunities to further their goal of developing novel therapies for patients impacted by rare endocrine disorders. For more information about Spruce Biosciences and their innovative therapies, visit their website or reach out to them via email